https://sleuro.fulgeas.com/improving-mortality-of-sle-patients-how-far-did-we-progress/ 2020-12-21T10:30:24+00:00 monthly 1.0 https://sleuro.fulgeas.com/lupus-quality-of-care-unmet-needs-for-bridging-the-gaps-across-multiple-healthcare-settings/ 2020-12-21T10:30:12+00:00 monthly 1.0 https://sleuro.fulgeas.com/is-sle-das-the-future-for-standardized-measure-of-disease-of-disease-activity-for-lupus-patients/ 2020-12-21T10:29:59+00:00 monthly 1.0 https://sleuro.fulgeas.com/2019-update-of-the-eular-recommendations-for-the-management-of-systemic-lupus-erythematosus/ 2020-12-21T10:29:48+00:00 monthly 1.0 https://sleuro.fulgeas.com/low-disease-activity-versus-remission-in-sle-is-it-ok-to-be-mediocre/ 2020-12-21T10:29:38+00:00 monthly 1.0 https://sleuro.fulgeas.com/tubular-cell-and-keratinocyte-single-cell-transcriptomics-in-lupus-nephritis/ 2020-12-21T10:29:27+00:00 monthly 1.0 https://sleuro.fulgeas.com/eular-recommendations-for-the-management-of-antiphospholipid-syndrome-in-adults/ 2020-12-21T10:29:16+00:00 monthly 1.0 https://sleuro.fulgeas.com/2019-eular-acr-sle-classification-criteria-in-practice/ 2020-12-21T10:29:07+00:00 monthly 1.0 https://sleuro.fulgeas.com/being-in-the-right-place-at-the-right-time-when-position-matters/ 2020-12-21T10:28:56+00:00 monthly 1.0 https://sleuro.fulgeas.com/toward-a-novel-prediction-marker-in-sle/ 2020-12-21T10:28:46+00:00 monthly 1.0 https://sleuro.fulgeas.com/trial-of-anifrolumab-in-active-systemic-lupus-erythematosus/ 2020-12-21T10:28:37+00:00 monthly 1.0 https://sleuro.fulgeas.com/withdrawal-of-low-dose-prednisone-in-sle-patients-with-a-clinically-quiescent-disease-for-more-than-1-year-a-randomised-controlled-trial/ 2020-12-21T10:28:29+00:00 monthly 1.0 https://sleuro.fulgeas.com/trial-in-anifrolumab-in-active-systemic-lupus-erythematosus/ 2020-12-21T10:28:16+00:00 monthly 1.0 https://sleuro.fulgeas.com/over-a-course-of-46-years-clinical-presentation-of-lupus-nephritis-ln-has-become-less-severe-in-the-last-years-leading-to-a-better-long-term-renal-survival-the-indispensable-role-of-renal-biopsy/ 2020-12-21T10:27:58+00:00 monthly 1.0 https://sleuro.fulgeas.com/lupus-nephritis-new-predictors-of-renal-outcomes-and-treatment-strategies-3/ 2020-12-21T09:31:01+00:00 monthly 1.0 https://sleuro.fulgeas.com/lupus-nephritis-new-predictors-of-renal-outcomes-and-treatment-strategies-2/ 2020-12-21T09:31:05+00:00 monthly 1.0 https://sleuro.fulgeas.com/lupus-nephritis-new-predictors-of-renal-outcomes-and-treatment-strategies/ 2020-12-21T09:46:10+00:00 monthly 1.0 https://sleuro.fulgeas.com/interferon-lambda-function-in-a-tlr7-induced-lupus-model/ 2021-01-18T14:30:07+00:00 monthly 1.0 https://sleuro.fulgeas.com/large-gwas-study-in-east-asian-individuals-with-sle/ 2021-01-18T14:41:25+00:00 monthly 1.0 https://sleuro.fulgeas.com/mapping-systemic-lupus-erythematosus-heterogeneity-at-the-single-cell-level/ 2021-03-17T09:44:22+00:00 monthly 1.0 https://sleuro.fulgeas.com/molecular-pathways-in-patients-with-systemic-lupus-erythematosus-revealed-by-gene-centred-dna-sequencing/ 2021-05-14T09:19:03+00:00 monthly 1.0 https://sleuro.fulgeas.com/effectiveness-of-mycophenolate-voclosporin-combination-therapy-in-lupus-nephritis/ 2021-05-14T09:18:38+00:00 monthly 1.0 https://sleuro.fulgeas.com/delineating-the-clinical-value-of-mmf-for-joint-manifestations/ 2021-07-13T13:48:43+00:00 monthly 1.0 https://sleuro.fulgeas.com/quality-indicators-for-systemic-lupus-erythematosus/ 2021-08-11T15:19:30+00:00 monthly 1.0 https://sleuro.fulgeas.com/towards-a-standardization-of-the-physican-global-assessment-pga-in-lupus/ 2022-06-30T08:03:28+00:00 monthly 1.0 https://sleuro.fulgeas.com/3085-2/ 2022-07-14T15:35:44+00:00 monthly 1.0 https://sleuro.fulgeas.com/hypomethylation-of-mir-17-92-cluster-in-lupus-t-cells-and-no-significant-role-of-genetic-factors-in-the-lupus-associated-dna-methylation-signature/ 2022-07-14T15:01:55+00:00 monthly 1.0 https://sleuro.fulgeas.com/comment-on-trial-of-anti-bdca2-antibody-litifilimab-for-cutaneous-lupus-erythematosus/ 2022-12-21T14:28:57+00:00 monthly 1.0 https://sleuro.fulgeas.com/lack-of-efficacy-of-ustekinumab-in-a-phase-3-randomised-controlled-trial-in-patients-with-systemic-lupus-erythematosus/ 2022-09-22T09:37:08+00:00 monthly 1.0 https://sleuro.fulgeas.com/stopping-versus-continuing-maintenance-immunosuppressive-therapy-in-lupus-nephritis-at-2-3-years/ 2022-09-22T09:38:12+00:00 monthly 1.0 https://sleuro.fulgeas.com/belimumab-use-during-pregnancy-a-summary-of-birth-defects-and-pregnancy-loss-from-belimumab-clinical-trials-a-pregnancy-registry-and-postmarketing-reports/ 2022-12-21T14:24:48+00:00 monthly 1.0 https://sleuro.fulgeas.com/always-listen-to-our-haematology-colleagues/ 2023-01-23T13:57:08+00:00 monthly 1.0 https://sleuro.fulgeas.com/global-epidemiology-of-systemic-lupus-erythematosus-a-comprehensive-systematic-analysis-and-modelling-study/ 2023-03-06T15:34:09+00:00 monthly 1.0 https://sleuro.fulgeas.com/cutting-steroids-may-improve-patient-reported-quality-of-life-blocking-interferon-works-on-many-types-of-skin-lupus-even-when-all-other-therapies-have-failed/ 2023-05-19T08:18:56+00:00 monthly 1.0 https://sleuro.fulgeas.com/blocking-interferon-works-on-many-types-of-skin-lupus-even-when-all-other-therapies-have-failed/ 2023-05-19T08:18:34+00:00 monthly 1.0 https://sleuro.fulgeas.com/finally-an-anti-cd20-antibody-meeting-endpoints-in-randomized-trials/ 2026-04-28T09:42:49+00:00 monthly 1.0 https://sleuro.fulgeas.com/a-high-burden-of-sle-risk-genes-is-associated-with-persistent-activation-of-the-interferon-system-in-patients-with-lupus/ 2026-05-26T15:23:51+00:00 monthly 1.0